Report Highlights
The global market for human reproductive technologies and products is valued at $16.1 billion in 2021 and is estimated to grow from $17.1 billion in 2022 to $24 billion in 2027 with a compound annual growth rate (CAGR) of 7% for the period of 2022-2027.
Report Includes
- 36 data tables and 22 additional tables
- An updated review of the global markets for human reproductive products and technologies
- Analyses of the global market trends, with data from 2020-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Evaluation and forecast the overall market size, projected growth trends, and corresponding market share analysis by treatment type, disease indication, end-user vertical, and geographic region
- In-depth information (facts and figures) concerning market drivers, market deterrents and other demographic and economic factors influencing the progress of this reproductive health market
- Discussion of the emerging technology trends, opportunities and gaps in the market estimating current and future demand for reproductive drugs and technologies, and COVID-19 implications within the marketplace
- Identification of promising new products and technologies still in the development and pipeline stage, and assess the probability that they will be commercialized successfully in the next five years
- Review of the company competitive landscape for global human reproductive drugs market, their product portfolios, global rankings, and company value share analysis based on segmental revenues
- Key merger and acquisition deals, new product launches, and other strategic alliances within the industry
- A relevant patent analysis
- Descriptive company profiles of the leading global players, including Actavis,Inc., Bayer AG, EMD Serono,Inc. and Quidel Corp.
Report Scope
The report is designed to be a comprehensive business tool to provide an in-depth look at the markets for reproductive drugs and technologies. The geographic scope of the report is global. The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health. The report also explores market size, identifies market participants, and investigates pipeline products and technologies.
The global market for reproductive technologies and products is divided into categories by treatment type and indication as follows.
Infertility market — male and female factors, pharmaceuticals, and future advancements.
- IVF.
- Assistive reproductive technologies.
- Fertility diagnostics.
Contraception — pharmaceuticals and devices.
Sexual dysfunction — pharmaceuticals and devices.
Each area is covered in detail, describing the disorder or treatment involved, identifying current products and treatments in the market in the base year 2021, measuring current market size and identifying current and potential market drivers, forecasting for 2027, assessing current and potential competitors, and identifying current competitor market shares for the base year of 2021.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2021 | ||||||||||||||||||
| Forecast period considered | 2022–2027 | ||||||||||||||||||
| Base year market size | $16.1 billion | ||||||||||||||||||
| Market size forecast | $24.0 billion | ||||||||||||||||||
| Growth rate | CAGR of 7.0% from 2022 to 2027 | ||||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||||
| Segments covered | Region, Product Type | ||||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) | ||||||||||||||||||
| Countries covered | U.S., Mexico., Canada., Germany., France., U.K., Italy., Spain., Rest of Europe (Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Sweden, Russia, etc.), Japan., China., India., Rest of Asia-Pacific (Australia, New Zealand, Taiwan, Singapore, Malaysia, Thailand, Philippines, Korea, Indonesia, etc.), (Middle East, Africa, South America). | ||||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||||
| Companies studied |
|
||||||||||||||||||
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets (HLC176E)
- Carbon Credits Market: Global Outlook (EGY200A)
- Drugs and Diagnostics for Hematological Disorders: Global Markets (PHM116C)
- Global Flame and Smoke Detectors Markets (MFG092A)
- Biodegradable Polymers: Global Markets and Technologies (PLS025K)
Report Highlights
The total market for reproductive technologies and products is estimated to achieve revenues of nearly $16.1 billion in 2013. In 2018, the forecasted revenues will likely reach $19.6 billion, demonstrating a compound annual growth rate (CAGR) of 4.1%.
Report Includes
- An overview of the market for human reproductive technologies.
- Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examinations of market sizes in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception, and sexual dysfunction, with a division of markets according to treatment type and indication.
- Evaluations of pipeline products and technologies.
- Patent analysis.
Report Highlights
-
The total U.S. market for reproductive technologies and products is estimated to be $6.5 billion in 2004. In 2009, revenues will likely reach $9.8 billion, rising at an average annual growth rate (AAGR) of 8.6%.
-
Contraceptive products currently account for the highest amount of revenues and are expected to grow at an AAGR of 9.1% through the period.
-
Sexual dysfunction products are expected to show the highest annual growth at an average of 12.3% through 2009.
-
Few areas in medicine have posed so many social and ethical questions and attracted so much public attention as has assisted reproductive technology (ART) to manage infertility.
Report Highlights
-
The total U.S. market for human reproductive technologies reached $6.9 billion in 2001. It is expected to rise at an AAGR (average annual growth rate) of 10.1% to $11 billion in 2006.
-
Treatments for infertility will show the most dynamic growth during the forecast period among reproductive technology products. The market for infertility treatments, both pharmaceuticals and procedures, is expected to exhibit an average annual growth rate (AAGR) of 19.7% from 2001 to 2006. Approximately 28% of the market in 2001 was generated by fertility drugs and the remainder of the market was contributed by revenues from assisted reproductive technologies (ARTs), primarily in vitro fertilization (IVF).
Related Reports
U.S. Fertility Clinics Market
The U.S. market for fertility clinic services is estimated to increase from $8.9 billion in 2023 to reach $16.8 billion by 2028, at a compound annual growth rate (CAGR) of 13.6% from 2023 through 2028.
Therapeutics for Women's Health: Technologies and Global Markets
The global market for women’s health therapeutics should grow from $54.4 billion in 2021 to $70.8 billion by 2026 with a compound annual growth rate (CAGR) of 5.4% for the period of 2021-2026.
Global Semen Analysis Market
The global market for semen analysis should grow from $407.2 million in 2021 to $592.8 million by 2026, at a compound annual growth rate (CAGR) of 7.8% for the period of 2021-2026.
Drugs for Infertility: Global Markets to 2022
The global market for drugs for infertility should reach $4.2 billion by 2022 from $3.4 billion in 2017 at a compound annual growth rate (CAGR) of 4.3%, from 2017 to 2022.
Recent Reports
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets
The global market for radiation therapy products and radiopharmaceuticals is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2024 to 2029.
Routine Health Screening Market
The global market for routine health screening is expected to grow from $59.7 billion in 2024 and is projected to reach $82.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2029.
Elder Care Services and Assistive Devices: Global Markets
The global market for elder care services and assistive devices is expected to grow from $868.2 billion in 2024 and is projected to reach $1.1 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 5.8% during the forecast period of 2024 to 2029.
Direct-to-Consumer Testing Industry: Global Markets
The global market for direct-to-consumer (DTC) testing is estimated to increase from $1.6 billion in 2023 to reach $3.2 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
Health and Medical Insurance Providers: Global Markets
The global market for health and medical insurance providers is expected to grow from $2.2 trillion in 2023 to $3.4 trillion by the end of 2028, at a compound annual growth rate (CAGR) of 8.9% during the forecast period of 2023 to 2028.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More